

- (51) International Patent Classification:

Not classified
- (21) International Application Number:

PCT/US2024/031755
- (22) International Filing Date:

30 May 2024 (30.05.2024)
- (25) Filing Language:

English
- (26) Publication Language:

English
- (30) Priority Data:

63/505,425      31 May 2023 (31.05.2023)      US
- (71) Applicant: BLUEJAY THERAPEUTICS, INC.

[US/US]; 400 Concar Drive, Suite 03-101, San Mateo, California 94402 (US).
- (72) Inventor: JAVANBAKHT, Hassan;

340 Fremont St. 2910, San Francisco, California 94105 (US).
- (74) Agent: SUN-HOFFMAN, Lin;

P.O. Box 52048, Palo Alto, California 94303 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-HBSAG ANTIBODY FOR TREATMENT OF CHRONIC HEPATITIS D




Fig. 1A

(57) Abstract: The present invention relates to anti-HBsAg antibodies, antibody fragments, and their uses for the prevention and treatment of hepatitis D virus infection and associated diseases. A method of neutralizing a hepatitis D virus infection comprising administering via injection or infusion to a patient in need an effective amount of the antibody, wherein said antibody or antigen binding fragment, is provided.